Release Date: February 20, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Biotricity I
Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NBTCY.PK - Biotricity IncQ3 2025 Biotricity Inc Earnings CallFeb 20, 2025 / 10:30PM GMT =======
Company expects to report Q3-FY25 revenue growth of 22% from the corresponding prior year quarter to $3.6 million ”“ an 11% increase sequentially from the imme
PR NewswireREDWOOD CITY, Calif., Dec. 27, 2024
Company Receives Capital Needed from its Term Lender and Existing Investors to Reach Profitability without a
PR NewswireREDWOOD CITY, Calif., Dec. 3, 2024
First Time in the Company's HistoryREDWOOD CITY, Calif., Dec. 3, 2024 /PRNewswire/ -- Biotricity Inc. (OTCQB:
Release Date: November 15, 2024For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Biotricity I
Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NBTCY.PK - Biotricity IncQ2 2025 Biotricity Inc Earnings CallNov 15, 2024 / 09:30PM GMT =======
The Global Patient Monitoring Devices Market Size was Valued at USD 48.23 Billion in 2023 and the Worldwide Patient Monitoring Devices Market Size is...
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms.
/PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small and...